Delivery Order SPE2DB22D2006-SPE2DB25FV7XL

Award Date 1/28/25
Potential Completion Date 1/29/25
Potential Value $5.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,519.08, is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, which is a vaccine product. The contract is a Firm Fixed Price Delivery Order with a completion date of February 7, 2025. While the original solicitation is not provided, the award indicates that this is part of a larger...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is a delivery order valued at $1,771.40 for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The contract has an ultimate completion date of January 28, 2025 and is a firm fixed price arrangement. This appears to be a task order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This federal contract award, valued at $56,178.60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with a completion date of November 15, 2024. The award is structured as a Firm Fixed Price Delivery Order contract, which is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $31,078.44, is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
This firm-fixed-price delivery order, valued at $14,981.12, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the government to efficiently procure a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The contract has a total ceiling value of $103,594.80 and runs through February 10, 2025. This appears to be a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with a ceiling value of $28,093.98 and a period of performance through January 8, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with a ceiling value of $60,913.20 and a completion date of January 23, 2025. The contract is a Delivery Order with a Firm Fixed Price pricing type. AmerisourceBergen Drug Corp is the prime contractor, and the contract is not...
This is a $46,466.50 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with a completion date of February 3, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $11,222.77, is for the delivery of 4566840253 – TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The contract is a Firm Fixed Price Delivery Order with a period of performance through January 7, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held...
  • SPE2DB22D2006
    Indefinite Delivery Contract
  • SPE2DB22D2006-SPE2DB25FV7XL
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,530.63, is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has a firm fixed-price pricing type and does not have a set-aside designation, indicating open competition.

Generated 5/4/25, 12:53 AM